Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis

Andrea Seaman, Erika Darrah, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Maurizio Benucci, Michael Mahler

Research output: Research - peer-reviewArticle

Abstract

Background: Recently, antibodies directed against peptidyl arginine deiminase 3 and 4 (anti-PAD3/PAD4 antibodies), calcium-dependent enzymes that catalyze the conversion from arginine to citrulline, have been described. Furthermore, antibodies that cross-react between PAD3 and PAD4 cause increased PAD4 activity and consequently correlate with joint damage. This study analyzes the correlation of anti-PAD3 antibodies with joint damage. Methods: To validate the novel chemiluminescent immunoassay (CIA) for the detection of anti-PAD3 antibodies, 20 samples were tested by CIA and by immunoprecipitation (IP). Next, 39 RA patients with available joint erosion score (JES), Total Sharp Score (TSS) and Joint Space Narrowing Score (JSNS) were tested for anti-CCP (using different methods) and anti-PAD3 antibodies by CIA. Results: Excellent correlation was observed between the CIA and IP for the detection of anti-PAD3 antibodies (rho = 0.85, p

LanguageEnglish (US)
JournalAutoimmunity Reviews
DOIs
StateAccepted/In press - Mar 7 2016

Fingerprint

Arginine
Rheumatoid Arthritis
Joints
Antibodies
Immunoassay
Immunoprecipitation
Citrulline
Calcium
Enzymes
arginine deiminase

Keywords

  • Autoantibodies
  • CCP
  • Citrullinated cyclic peptide
  • PAD
  • Peptidyl arginine deiminase
  • RA
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis. / Seaman, Andrea; Darrah, Erika; Infantino, Maria; Meacci, Francesca; Manfredi, Mariangela; Benucci, Maurizio; Mahler, Michael.

In: Autoimmunity Reviews, 07.03.2016.

Research output: Research - peer-reviewArticle

Seaman, Andrea ; Darrah, Erika ; Infantino, Maria ; Meacci, Francesca ; Manfredi, Mariangela ; Benucci, Maurizio ; Mahler, Michael. / Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis. In: Autoimmunity Reviews. 2016
@article{d14a1a300a00495daef73b74b17a4a10,
title = "Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis",
abstract = "Background: Recently, antibodies directed against peptidyl arginine deiminase 3 and 4 (anti-PAD3/PAD4 antibodies), calcium-dependent enzymes that catalyze the conversion from arginine to citrulline, have been described. Furthermore, antibodies that cross-react between PAD3 and PAD4 cause increased PAD4 activity and consequently correlate with joint damage. This study analyzes the correlation of anti-PAD3 antibodies with joint damage. Methods: To validate the novel chemiluminescent immunoassay (CIA) for the detection of anti-PAD3 antibodies, 20 samples were tested by CIA and by immunoprecipitation (IP). Next, 39 RA patients with available joint erosion score (JES), Total Sharp Score (TSS) and Joint Space Narrowing Score (JSNS) were tested for anti-CCP (using different methods) and anti-PAD3 antibodies by CIA. Results: Excellent correlation was observed between the CIA and IP for the detection of anti-PAD3 antibodies (rho = 0.85, p",
keywords = "Autoantibodies, CCP, Citrullinated cyclic peptide, PAD, Peptidyl arginine deiminase, RA, Rheumatoid arthritis",
author = "Andrea Seaman and Erika Darrah and Maria Infantino and Francesca Meacci and Mariangela Manfredi and Maurizio Benucci and Michael Mahler",
year = "2016",
month = "3",
doi = "10.1016/j.autrev.2016.03.016",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis

AU - Seaman,Andrea

AU - Darrah,Erika

AU - Infantino,Maria

AU - Meacci,Francesca

AU - Manfredi,Mariangela

AU - Benucci,Maurizio

AU - Mahler,Michael

PY - 2016/3/7

Y1 - 2016/3/7

N2 - Background: Recently, antibodies directed against peptidyl arginine deiminase 3 and 4 (anti-PAD3/PAD4 antibodies), calcium-dependent enzymes that catalyze the conversion from arginine to citrulline, have been described. Furthermore, antibodies that cross-react between PAD3 and PAD4 cause increased PAD4 activity and consequently correlate with joint damage. This study analyzes the correlation of anti-PAD3 antibodies with joint damage. Methods: To validate the novel chemiluminescent immunoassay (CIA) for the detection of anti-PAD3 antibodies, 20 samples were tested by CIA and by immunoprecipitation (IP). Next, 39 RA patients with available joint erosion score (JES), Total Sharp Score (TSS) and Joint Space Narrowing Score (JSNS) were tested for anti-CCP (using different methods) and anti-PAD3 antibodies by CIA. Results: Excellent correlation was observed between the CIA and IP for the detection of anti-PAD3 antibodies (rho = 0.85, p

AB - Background: Recently, antibodies directed against peptidyl arginine deiminase 3 and 4 (anti-PAD3/PAD4 antibodies), calcium-dependent enzymes that catalyze the conversion from arginine to citrulline, have been described. Furthermore, antibodies that cross-react between PAD3 and PAD4 cause increased PAD4 activity and consequently correlate with joint damage. This study analyzes the correlation of anti-PAD3 antibodies with joint damage. Methods: To validate the novel chemiluminescent immunoassay (CIA) for the detection of anti-PAD3 antibodies, 20 samples were tested by CIA and by immunoprecipitation (IP). Next, 39 RA patients with available joint erosion score (JES), Total Sharp Score (TSS) and Joint Space Narrowing Score (JSNS) were tested for anti-CCP (using different methods) and anti-PAD3 antibodies by CIA. Results: Excellent correlation was observed between the CIA and IP for the detection of anti-PAD3 antibodies (rho = 0.85, p

KW - Autoantibodies

KW - CCP

KW - Citrullinated cyclic peptide

KW - PAD

KW - Peptidyl arginine deiminase

KW - RA

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84963506637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963506637&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2016.03.016

DO - 10.1016/j.autrev.2016.03.016

M3 - Article

JO - Autoimmunity Reviews

T2 - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -